MB
Therapeutic Areas
F2G Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Olorofim (F901318) | Invasive fungal infections (e.g., aspergillosis, including azole-resistant; infections due to Lomentospora prolificans, Scedosporium spp., and fungi in the order Mucorales) | Phase 3 |